Australian Pharmaceutical Industries Ltd (ASX: API) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Australian Pharmaceutical Industries Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $751.30 million
P/E Ratio 526.32
Dividend Yield 2.34%
Shares Outstanding 492.66 million
Earnings per share 0.003
Dividend per share 0.04
Year To Date Return -13.58%
Earnings Yield 0.19%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Australian Pharmaceutical Industries Ltd (ASX: API)
Latest News

A man and woman sit next to each other looking at each other and feeling excited and surprised after reading good news about their ASX shares on the laptop in front of them
Consumer Staples & Discretionary Shares

Could this signal the next big acquisition for Wesfarmers (ASX:WES)?

Key points The Wesfarmers share price is down 5% today There are talks of Wesfarmers setting up a healthcare fund …

Read more »

a woman sitting at a desk checks an old fashioned calendar resting against her wall as she sits with documents in front of her.
Mergers & Acquisitions

Following the Wesfarmers (ASX:WES) API takeover? Here are some key dates to watch out for

It’s been a wild rise for market watchers interested in Wesfarmers Ltd‘s (ASX: WES) takeover of Australian Pharmaceuticals Industries Ltd …

Read more »

share price plummeting down
Share Fallers

Why API, James Hardie, Magellan, and St Barbara shares are dropping

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is back on form and charging higher. At the time of writing, …

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Share Market News

ASX 200 (ASX:XJO): Woolworths withdraws API proposal, tech shares rebound

At lunch on Friday, the S&P/ASX 200 Index (ASX: XJO) is rebounding from yesterday’s selloff. The benchmark index is currently up …

Read more »

woman looks shocked at mobile phone
Mergers & Acquisitions

API (ASX:API) share price crashes 12% after Woolworths withdraws takeover offer

The Australian Pharmaceutical Industries Ltd (ASX: API) share price has come under pressure on Friday. This follows news that Woolworths …

Read more »

a man sits back from his laptop computer with both hands behind his head as though he is greatly satisfied with a smile on his face.
Mergers & Acquisitions

Wesfarmers (ASX:WES) share price higher after receiving API takeover boost

The Wesfarmers Ltd (ASX: WES) share price is pushing higher on Friday morning. In early trade, the conglomerate’s shares are …

Read more »

ASX 200 shares broker downgrade origami paper fortune teller with buy hold sell and dollar sign options
Retail Shares

Is the Wesfarmers (ASX:WES) share price an opportunity right now?

The Wesfarmers Ltd (ASX: WES) share price is in focus after a period of strong growth from the effects of …

Read more »

a business person in a suit and tie directs a pointed finger upwards with a graphic of a rising bar graph and an arrow heading upwards in line with the person's finger.
Consumer Staples & Discretionary Shares

Woolworths (ASX:WOW) share price rises as boss courts API pharmacists

The Woolworths Group Ltd (ASX: WOW) share price is up 0.5% in early trading. The CEO of Woolworths is trying …

Read more »

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
11 Nov 2021 $0.0200 100.00% Final 15 Dec 2021
06 May 2021 $0.0150 100.00% Interim 04 Jun 2021
11 Nov 2020 $0.0200 100.00% Final 15 Dec 2020
13 Nov 2019 $0.0400 100.00% Final 12 Dec 2019
02 May 2019 $0.0375 100.00% Interim 31 May 2019
08 Nov 2018 $0.0400 100.00% Final 07 Dec 2018
03 May 2018 $0.0350 100.00% Interim 01 Jun 2018
09 Nov 2017 $0.0350 100.00% Final 08 Dec 2017
04 May 2017 $0.0350 100.00% Interim 02 Jun 2017
03 Nov 2016 $0.0350 100.00% Final 09 Dec 2016
05 May 2016 $0.0250 100.00% Interim 03 Jun 2016
04 Nov 2015 $0.0250 100.00% 04 Dec 2015
06 May 2015 $0.0200 100.00% 05 Jun 2015
12 Nov 2014 $0.0200 100.00% 12 Dec 2014
07 May 2014 $0.0150 100.00% 06 Jun 2014
11 Nov 2011 $0.0150 0.00% Final 15 Dec 2011

API ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Australian Pharmaceutical Industries Ltd

Australian Pharmaceutical Industries Ltd (ASX: API) is an Australian company with three key areas of operation: retail, wholesale distribution and business advisory. The company is probably best known for its retail pharmacy and health and beauty brands, Soul Pattinson and Priceline.

Priceline was acquired by API in 2004 and has more than 420 stores Australia-wide. Priceline stores are wholly owned by API whereas Priceline Pharmacies are operated under a franchise model.

In addition to its pharmacy brands, API owns a chain of 57 cosmetic, skin and laser hair removal clinics in Australia and New Zealand called Clear Skincare Clinics. It also produces a range of products under the Clear Skincare brand which it sells through Priceline Pharmacy.

API’s operations include retail services which encompass marketing programs and business advice.

API was established in 1910 and listed on the ASX in 1997. The API share price was hit hard by the February/March 2020 bear market, falling as low as $1 on 23 March. Since then, as at October 2020, the API share price has continued trading at between $1 and $1.20.

API Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
28 Jan 2022 $1.53 $0.03 2.01% 4,026,086 $1.50 $1.53 $1.50
27 Jan 2022 $1.50 $0.00 0.00% 3,370,476 $1.50 $1.51 $1.49
25 Jan 2022 $1.50 $-0.01 -0.66% 4,452,770 $1.51 $1.52 $1.50
24 Jan 2022 $1.52 $0.00 0.00% 1,364,288 $1.51 $1.52 $1.51
21 Jan 2022 $1.51 $-0.01 -0.66% 4,340,570 $1.52 $1.52 $1.51
20 Jan 2022 $1.52 $0.00 0.00% 1,731,524 $1.52 $1.53 $1.52
19 Jan 2022 $1.52 $0.01 0.66% 1,016,598 $1.52 $1.52 $1.52
18 Jan 2022 $1.52 $-0.01 -0.66% 365,624 $1.52 $1.52 $1.52
17 Jan 2022 $1.52 $0.01 0.66% 702,034 $1.52 $1.52 $1.52
14 Jan 2022 $1.52 $0.00 0.00% 833,031 $1.52 $1.52 $1.52
13 Jan 2022 $1.52 $-0.01 -0.66% 1,631,678 $1.52 $1.53 $1.52
12 Jan 2022 $1.52 $0.01 0.66% 575,312 $1.52 $1.53 $1.52
11 Jan 2022 $1.52 $0.00 0.00% 403,807 $1.52 $1.52 $1.52
10 Jan 2022 $1.52 $0.00 0.00% 2,820,858 $1.52 $1.52 $1.52
07 Jan 2022 $1.52 $-0.22 -12.72% 4,975,821 $1.53 $1.54 $1.51
06 Jan 2022 $1.73 $-0.01 -0.57% 1,332,922 $1.74 $1.75 $1.72
05 Jan 2022 $1.74 $0.01 0.58% 295,674 $1.74 $1.74 $1.73
04 Jan 2022 $1.73 $0.00 0.00% 281,278 $1.73 $1.74 $1.73
31 Dec 2021 $1.73 $0.00 0.00% 292,107 $1.73 $1.74 $1.73
30 Dec 2021 $1.73 $0.00 0.00% 148,928 $1.73 $1.74 $1.73

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
15 Oct 2021 Richard Vincent Expiry 416 $633,770
As advised by the company. 1,482,011 - Performance Rights
Performance rights lapsed under API's Long
Term Incentive Plan
15 Oct 2021 Richard Vincent Issued 160 $244,568
Issue of securities. 1,898,965 - performance rights
03 Feb 2021 Richard Vincent Issued 825 $1,056,512
Issue of securities. 1,738,065 - performance rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Richard Craig Vincent Chief Executive OfficerManaging Director Feb 2017
Mr Vincent started his professional career in finance with Bridgestone before moving to Britax Rainsfords where he was CFO. He joined FH Faulding & Co Limited (ultimately acquired by the Mayne Group) in 1998 and remained with that company until 2005, during which time he held a number of senior leadership roles, including responsibility for the pharmacy distribution, retail merchandise and generic pharmaceutical development. Mr Vincent joined API in 2005. He has held a number of general management roles including pharmacy distribution and business development, strategy, supply chain, franchise recruitment, IT, manufacturing and mergers and acquisition. Mr Vincent is the Chair of the National Pharmaceutical Services Association and was also a Director of CH2 Holdings Pty Ltd from 2006 to 2015.
Mr Kenneth William Gunderson-Briggs Non-Executive DirectorNon-Executive Chairman May 2014
Mr Gunderson-Briggs is a chartered accountant in public practice, registered company auditor and public company Director, with experience in finance and the retail franchise sectors. Mr Gunderson-Briggs was a Director of Glenaeon Rudolf Steiner School Limited from 2009 until May 2018, and its Chair from 2013 until May 2018.
Ms Lee Ausburn Non-Executive Director Oct 2008
Ms Ausburn is a pharmacist with experience in retail and hospital pharmacy and in academia. She had a long career in the pharmaceutical industry with Merck Sharp and Dohme (Australia) Pty Ltd and was previously Vice President, Asia, for Merck and Co Inc with responsibility for the company's operations across Asia. Ms Ausburn was President, Pharmacy Faculty Foundation, University of Sydney until December 2017.
Ms Jennifer (Jenny) Mitchell Macdonald Non-Executive Director Nov 2017
Ms Macdonald has a background in financial and general management roles across a range of industry sectors including fast moving consumer goods, travel and digital media. Ms Macdonald was previously Chief Financial Officer and Interim Chief Executive Officer at Helloworld Travel and Chief Financial Officer and General Manager International at REA Group.
Ms Janine Suzanne Allis Non-Executive Director Oct 2020
Ms Allis is a businesswoman with experience in retail and franchising. Ms Allis founded Boost Juice Bars and the Retail Zoo group of food retail brands and has led innovation in digital marketing and customer engagement. Ms Allis has won numerous retail and franchise awards and has been appointed an Ambassador to the United Nations High Commission for Refugees. She is currently a non-executive Director of the Olivia Newton-John Foundation and was previously a director of the Hawthorn Football Club. She is Member of People and Remuneration Committee.
Mr Clive Stiff Non-Executive Director Dec 2020
Mr Stiff has over 35 years' experience in fast moving consumer goods. He is the former CEO of Unilever Australia & New Zealand and prior to that held a range of senior management roles locally with Goodman Fielder and internationally with Procter & Gamble. Mr Stiff was previously the Chair of the Australian Food & Grocery Council, the Chair of T2 Tea and a non-executive director of Foodbank NSW & ACT. He is currently the non-executive Chair of All G Foods Pty Ltd, a member of the Quantium Advisory Board and a member of the Genpact Australian Advisory Council. He is an external advisor to Bain & Company and a member of the University of New South Wales Business School Advisory Council.
Mr George Tambassis Non-Executive Director Jun 2021
Mr Tambassis is a pharmacist with over 35 years' operational experience in community pharmacies. He has served as a director of the Australian College of Pharmacy, as a director of an aged care facility and as a member of the Australian Community Pharmacy Authority. He was the inaugural President of the World Pharmacy Council and a member of the OECD's Associate Expert Group advising on pharmacy and health. Mr Tambassis served as a director on the Pharmacy Guild of Australia for 15 years including 7.5 as its National President, during which he was instrumental in concluding the 6th and 7th Community Pharmacy Agreements with the Commonwealth Government.
Ms Anne Mustow Company SecretaryGeneral Counsel Jul 2019
-
Peter Mendo Chief Financial Officer
-
Anne Mustow Company SecretaryGeneral Counsel
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Wesfarmers Limited 95,068,472 19.30%
Citicorp Nominees Pty Limited 80,571,205 16.35%
HSBC Custody Nominees (Australia) Limited 64,649,846 13.12%
J P Morgan Nominees Australia Pty Limited 47,045,778 9.55%
National Nominees Limited 23,990,229 4.87%
Neweconomy Com Au Nominees Pty Limited <900 Account> 10,875,648 2.21%
BNP Paribas Noms Pty Ltd <Drp> 5,487,767 1.11%
BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 3,446,978 0.70%
HSBC Custody Nominees (Australia) Limited A/C 2 3,127,021 0.63%
Brispot Nominees Pty Ltd <House Head Nominee A/C> 2,406,099 0.49%
J & P Chick Pty Limited <J & P Chick Pty Ltd S/F A/C> 2,000,000 0.41%
Jum Pty Limited 1,567,286 0.32%
Netwealth Investments Limited <Wrap Services A/C> 1,564,064 0.32%
HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 1,562,450 0.32%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 1,502,889 0.31%
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 1,461,003 0.30%
Dr Jeffrey Eric Dale Chick & Dr Pamela Hazel Chick 1,260,000 0.26%
Mr Frederick Benjamin Warmbrand <Fb & Lj Warmbrand Super A/C> 1,240,000 0.25%
UBS Nominees Pty Ltd 898,087 0.18%
Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> 889,410 0.18%

Profile

since

Note